Form 4: Abbott Director Michael O'Grady Receives Equity Grant
Statement of Changes in Beneficial Ownership
Abbott Laboratories director Michael O'Grady was granted 2,286 restricted stock units and 5,929 stock options as part of the 2026 Incentive Stock Program.
Summary
- Director Michael O'Grady received an award of 2,286 restricted stock units (RSUs) on April 24, 2026.
- The director was also granted 5,929 stock options with an exercise price of $91.86.
- The RSUs will be settled in common shares upon separation from service, death, or a change in control.
- The stock options have an expiration date of April 23, 2036.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation that carries no material impact on the company's financial outlook.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
- Standard incentive structure under the company's 2026 Incentive Stock Program.
Negatives
- None identified; this is a routine disclosure of director compensation.
Risks
- Market volatility affecting the value of equity-based compensation.
- Regulatory risks associated with compliance under Section 16 of the Securities Exchange Act.
Future Outlook
The filing does not provide forward-looking financial guidance, as it is a routine disclosure of director equity compensation.
Industry Context
StockSavvy.ai notes that equity grants to board members are standard practice in the healthcare and pharmaceutical sectors to ensure long-term alignment with corporate governance and shareholder interests.
Comparison to Industry Standards
- The use of RSUs and stock options for director compensation is consistent with practices at peer companies like Medtronic, Danaher, and Thermo Fisher Scientific.
- The vesting and settlement terms align with standard corporate governance practices for non-employee directors.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Updated authorization for attorneys-in-fact to file SEC documents. | 06/13/2025 | Ensures continued compliance with SEC reporting requirements. |
Stakeholder Impact
- Minimal impact on shareholders; reflects standard director compensation practices.
Next Steps
- The director will hold these securities until the specified vesting or separation events occur.
Key Dates
| Date | Description |
|---|---|
| 06/13/2025 | Date of Power of Attorney signature. |
| 04/24/2026 | Date of transaction and grant of equity awards. |
| 04/28/2026 | Date of filing. |
| 04/23/2036 | Expiration date of stock options. |
Keywords
Abbott Laboratories, ABT, Form 4, Director Compensation, Equity Grant, Insider Trading, Stock Options
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.